Faecal markers of gastrointestinal inflammation

Journal of Clinical Pathology

Volumn 65, Issue 11, 2012, Pages 981-985

  Sherwood, Roy A ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM BINDING PROTEIN; CALGRANULIN; LACTOFERRIN; PYRUVATE KINASE; S100A12 PROTEIN; UNCLASSIFIED DRUG;

CLINICAL ASSESSMENT; CROHN DISEASE; DIFFERENTIAL DIAGNOSIS; DIGESTIVE SYSTEM INFLAMMATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FECES ANALYSIS; GOLD STANDARD; HUMAN; IRRITABLE COLON; POINT OF CARE TESTING; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; REVIEW; SENSITIVITY AND SPECIFICITY; ULCERATIVE COLITIS;

BIOLOGICAL MARKERS; COLITIS, ULCERATIVE; CROHN DISEASE; DIAGNOSIS, DIFFERENTIAL; FECES; GASTROENTERITIS; HUMANS; INFLAMMATORY BOWEL DISEASES; IRRITABLE BOWEL SYNDROME; LACTOFERRIN; LEUKOCYTE L1 ANTIGEN COMPLEX; PRACTICE GUIDELINES AS TOPIC; PYRUVATE KINASE; S100 PROTEINS;

EID: 84867909695     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jclinpath-2012-200901     Document Type: Review

References (47)

1. Dolwani S, Metzner M, Wassell JJ, et al. Diagnostic accuracy of faecal calprotectin estimation in prediction of abnormal small bowel radiology. Aliment Pharmacol Ther 2004;20:615-21. (Pubitemid 39279049)
2. Dale I, Brandtzaeg P, Fagerhol MK, et al. Distribution of a new myelomonocytic antigen (L1) in human peripheral blood leukocytes. Immunofluorescence and immunoperoxidase staining features in comparison with lysozyme and lactoferrin. Am J Clin Pathol 1985;84:24-34. (Pubitemid 15240214)
3. Tibble JA, Sigthorsson G, Bridger S, et al. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterol 2000;119:15-22. (Pubitemid 30452574)
4. Tibble JA, Sigthorsson G, Foster R, et al. Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease. Gastroenterol 2002;123:450-60. (Pubitemid 34827189)
5. Centre for Evidence-based Puchasing. Evidence review: value of calprotectin in screening out irritable bowel syndrome. London: NHS Purchasing and Supply Agency, 2009:CEP09026.
6. Gisbert JP, McNicholl AG. Questions and answers on the role of faecal calprotectin as a biological marker in inflammatory bowel disease. Dig Liver Dis 2009;41:56-66.
7. Konikoff MR, Denson LA. Role of fecal calprotectin as a biomarker of intestinal inflammation in inflammatory bowel disease. Inflamm Bowel Dis 2006;12:524-34.
8. Van Roon AC, Karamountzos L, Purkayastha S, et al. Diagnostic precision of fecal calprotectin for inflammatory bowel disease and colorectal malignancy. Am J Gastroenterol 2007;102:803-13. (Pubitemid 46496634)
9. Gearry R, Barclay M, Florkowski C, et al. Faecal calprotectin: the case for a novel non-invasive way of assessing intestinal inflammation. NZ Med J 2005;118:U1444.
10. Shastri YM, Bergis D, Pouse N, et al. Prospective multicenter study evaluating fecal calprotectin in adult acute bacterial diarrhoea. Am J Med 2008;12:1099-106.
11. Sykora J, Siala K, Huml M, et al. Evaluation of faecal calprotectin as a valuable non-invasive marker in distinguishing gut pathogens in young children with acute gastroenteritis. Acta Paediatr 2010;99:1389-95.
12. Limburg PJ, Devens ME, Harrington JJ, et al. Prospective evaluation of faecal calprotectin as a screening biomarker for colorectal neoplasia. Am J Gastroenterol 2003;98:2299-305. (Pubitemid 37305374)
13. Tursi A, Brandimarte G, Elisei W, et al. Faecal calprotectin in chronic diverticular disease: a case-control study. Int J Colorectal Dis 2008;24:49-55.
14. Otten CM, Koh L, Witteman BJ, et al. Diagnostic performance of rapid tests for detection of fecal calprotectin and lactoferrin and their ability to discriminate inflammatory from irritable bowel syndrome. Clin Chem Lab Med 2008;46:1275-80.
15. Vestergaard TA, Nielsen SL, Dahlerup JF, et al. Fecal calprotectin: assessment of a rapid test. Scand J Clin Lab Invest 2008;68:343-7. (Pubitemid 351962410)
16. Damms A, Bischoff SC. Validation and clinical significance of a new calprotectin rapid test for the diagnosis of gastrointestinal diseases. Int J Colorectal Dis 2008;23:985-92.
17. Johnson L, McHenry A, Awais D, et al. Correlation and variability in fecal calprotectin measurements. Inflamm Bowel Dis 2008;14:S41-2.
18. Husebye E, Ton H, Johne B. Biological variability of fecal calprotectin in patients referred for colonoscopy without colonic infl ammation or neoplasm. Am J Gastroenterol 2001;96:2683-7.
19. Tibble JA, Sigthorsson G, Foster R, et al. High prevalence of NSAID enteropathy as shown by a simple faecal test. Gut 1999;45:362-6. (Pubitemid 29400711)
20. Whitehead SJ, French J, Brookes MJ, et al. Between-assay variability of faecal calprotectin enzyme-linked immunosorbent assay kits. Ann Clin Biochem 2012, in press.
21. Hardt PD, Mazurek S, Toepler M, et al. Faecal tumour M2 pyruvate kinase: a new, screening tool for colorectal cancer. Br J Cancer 2004;91:980-4. (Pubitemid 39273794)
22. Chung-Faye G, Hayee B, Maestranzi S, et al. Fecal M2-pyruvate kinase (M2-PK): a novel marker of intestinal inflammation. Inflamm Bowel Dis 2007;13:1374-8. (Pubitemid 350206848)
23. Czub E, Herzig KH, Szaflarska-Popawska A, et al. Fecal pyruvate kinase: a potential new marker for intestinal inflammation in children with inflammatory bowel disease. Scand J Gastroenterol 2007;42:1147-50. (Pubitemid 47537095)
24. Jeffrey J, Lewis SJ, Ayling RM. Fecal dimeric M2-pyruvate kinase (tumor M2-PK) in the differential diagnosis of functional and organic bowel disorders. Inflamm Bowel Dis 2009;15 :1630-4.
25. Turner D, Leach ST, Mack D, et al. Faecal calprotectin, lactoferrin, M2-pyruvate kinase and S100A12 in severe ulcerative colitis: a prospective multicentre comparison of predicting outcome and monitoring response. Gut 2010;59:1207-12.
26. Masson PL, Heremans JF. Studies on lactoferrin, the iron binding protein of secretions. Protides Biol Fluid 1966;14:115-24.
27. Martins CA, Fonteles MG, Barrett LJ, et al. Correlation of lactoferrin with neutrophilic inflammation in body fluids. Clin Diagn Lab Immunol 1995;2:763-5.
28. Guerrant RL, Arauja V, Soares E, et al . Measurement of fecal lactoferrin as a marker of fecal leucocytes. J Clin Microbiol 1992;30:1238-42.
29. Gisbert JP, McNicholl AG, Gomollen F. Questions and answers on the role of fecal lactoferrin as a biological marker in infl ammatory bowel disease. Inflamm Bowel Dis 2009;15:1746-54.
30. Kane SV, Sandborn WJ, Rufo PA, et al. Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation. Am J Gastroenterol 2003;98:1309-14. (Pubitemid 36741528)
31. Schröder O, Naumann M, Shastri Y, et al. Prospective evaluation of fecal neutrophil-derived proteins in identifying intestinal inflammation: combination of parameters does not improve diagnostic accuracy of calprotectin. Aliment Pharmacol Ther 2007;26:1035-42. (Pubitemid 47416301)
32. D'Inca R, Dal Pont E, Di Leo V, et al. Calprotectin and lactoferrin in the assessment of intestinal inflammation and organic disease. Int J Colorectal Dis 2007;22:429-37. (Pubitemid 46336248)
33. Langhorst J, Elsenbruch S, Mueller T, et al. Comparison of 4 neutrophil-derived proteins in feces as indicators of disease activity in ulcerative colitis. Inflamm Bowel Dis 2005;11:1085-91. (Pubitemid 41682565)
34. Langhorst J, Elsenbruch S, Koelzer J, et al. Non-invasive markers in the assessment of intestinal inflammation in inflammatory bowel disease: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. Am J Gastroenterol 2008;103:162-9.
35. Schoepfer AM, Trummler M, Seeholzer P, et al. Accuracy of four fecal assays in the diagnosis of colitis. Dis Colon Rectum 2007; 50:1440-4.
36. Schoepfer AM, Trummler M, Seeholzer P, et al. Discriminating IBD from IBS: a comparison of the test performance of fecal markers, blood leucocytes, CRP, and IBD antibodies. Inflamm Bowel Dis 2008;14:32-9. (Pubitemid 351196866)
37. Dai J, Liu WZ, Zhau YP, et al. Relationship between fecal lactoferrin and inflammatory bowel disease. Scand J Gastroenterol 2007;42:1440-4. (Pubitemid 350125546)
38. Walker TR, Land ML, Kartashow A, et al. Fecal lactoferrin is a sensitive and specific marker of disease activity in children and young adults with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007;44 :414-22. (Pubitemid 46573222)
39. Ashraf H, Beltinger J, Alam NH, et al. Evaluation of fecal occult blood test and lactoferrin latex agglutination test in screening hospitalized patients for diagnosis of inflammatory and non-inflammatory diarrhoea in Dhaka, Bangladesh. Digestion 2007;76:256-61. (Pubitemid 351351683)
40. Parsi MA, Shen BO, Ackkan JP, et al. Fecal lactoferrin for diagnosis of symptomatic patients with ileal pouch-anal anastomosis. Gastroenterol 2004;126:1280-6. (Pubitemid 38552792)
41. Kaiser T, Langhorst J, Wittkowski H, et al. Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome. Gut 2007;56:1706-9.
42. Sidler MA, Leach ST, Day AS. Fecal S100A12 and fecal calprotectin as non-invasive markers for inflammatory bowel disease in children. Inflamm Bowel Dis 2008;14:359-66. (Pubitemid 351441325)
43. De Jong NS, Leach ST, Day AS. Fecal S100A12: a novel non-invasive marker in children with Crohn's disease. Inflamm Bowel Dis 2006;12:566-72. (Pubitemid 43977737)
44. Ayling RM. New faecal tests in gastroenterology. Ann Clin Biochem 2012;49:44-54.
45. NICE, Diagnosis and management of irritable bowel syndrome in primary care. 2008. NICE clinical guideline 61.
46. Schoepfer AM, Beglinger C, Straumann A, et al. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's Disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol 2010;105:162-9.
47. Lamb CA, Mohiuddin MK, Gicquel J, et al. Fecal calprotectin or lactoferrin can identify postoperative recurrence in Crohn's disease. Br J Surg 2009;96:663-74.